Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06380751 · ClinicalTrials.gov registry record · Phase 3

Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer

A Phase 3 study of Advanced Breast Cancer, sponsored by AstraZeneca.

Recruiting
Registry status
Phase 3
Development phase
500
Enrollment target
20
Study locations

NCT06380751 is a Phase 3 study of Advanced Breast Cancer that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 500 participants, above the 447-participant average among 28 other Advanced Breast Cancer trials with a reported enrollment target (12% higher). The trial reports 20 study locations across 8 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06380751, a Phase 3 study of Advanced Breast Cancer, is actively recruiting participants, sponsored by AstraZeneca.

RECRUITING
Registry status
Phase 3
Development phase
500 participants
Enrollment target
20
Study locations

Study Summary

The primary objective of the study is to measure efficacy of saruparib (AZD5305) plus camizestrant compared with physician's choice CDK4/6i plus ET in patients with BRCA1, BRCA2, or PALB2m, HR-positive, HER2-negative (defined as IHC 0, 1+, 2+/ ISH non-amplified) advanced breast cancer

Conditions Studied

Advanced Breast Cancer

Interventions

  • DRUG Saruparib (AZD5305)
  • DRUG Camizestrant
  • DRUG Palbociclib
  • DRUG Abemaciclib
  • DRUG Ribociclib

Study Locations (20)

Illinois

  • Research Site - Chicago
  • Research Site - Evanston
  • Research Site - Park Ridge
  • Research Site - Urbana
  • Research Site - Winfield

California

  • Research Site - Fountain Valley
  • Research Site - Glendale
  • Research Site - Los Angeles
  • Research Site - Newport Beach

Florida

  • Research Site - Hollywood
  • Research Site - Jacksonville
  • Research Site - Orlando

Maryland

  • Research Site - Baltimore
  • Research Site - Silver Spring
  • Research Site - Silver Spring

Colorado

  • Research Site - Aurora
  • Research Site - Grand Junction

Arizona

  • Research Site - Gilbert

Indiana

  • Research Site - Indianapolis

Kentucky

  • Research Site - Louisville

Trial Details

FieldValue
Enrollment Target 500 participants
Start Date 2024-08-01
Est. Completion 2030-10-18
Phase Phase 3

Sponsor

AstraZeneca

1,285 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06380751

The ClinicalTrials.gov registry entry for NCT06380751 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 500 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 447-participant average among 28 other Advanced Breast Cancer trials with a reported enrollment target (12% higher). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Advanced Breast Cancer appearing as the primary indexed condition, and to 5 interventions - of which Saruparib (AZD5305) is the first listed.

NCT06380751 reports 20 study locations spanning 8 distinct geographic areas - top geographies include Illinois, California, Florida.

Frequently Asked Questions

What is clinical trial NCT06380751 about?

NCT06380751 is a clinical study titled "Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer". The primary objective of the study is to measure efficacy of saruparib (AZD5305) plus camizestrant compared with physician's choice CDK4/6i plus ET in patients with BRCA1, BRCA2, or PALB2m, HR-positive, HER2-negative (defined as IHC 0, 1+, 2+/ ISH non-amplified) advanced breast cancer

What is the current status of trial NCT06380751?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 500 participants. The study started on 2024-08-01. Estimated completion is 2030-10-18.

What conditions does trial NCT06380751 study?

This clinical trial studies the following conditions: Advanced Breast Cancer.

What interventions are being tested in trial NCT06380751?

The interventions under investigation include: Saruparib (AZD5305) (DRUG), Camizestrant (DRUG), Palbociclib (DRUG), Abemaciclib (DRUG), Ribociclib (DRUG).

Who is sponsoring clinical trial NCT06380751?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06380751 being conducted?

This trial has 20 study locations across Arizona, California, Colorado, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Advanced Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Advanced Breast Cancer

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.